Therapeutic Indications

Anagrelide is indicated for:

Essential thrombocythemia

Irrespective of gender only Adults (18 years old or older)

Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

An at risk patient

An at risk essential thrombocythaemia patient is defined by one or more of the following features:

  • >60 years of age or
  • a platelet count >1000 × 109/l or
  • a history of thrombo-haemorrhagic events.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 1-10 mg/day in two divided doses

Contraindications

Active ingredient Anagrelide is contraindicated in the following cases:

Moderate or severe renal impairment

No gender/age discrimination

There are limited pharmacokinetic data for this patient population. The potential risks and benefits of anagrelide therapy in a patient with impairment of renal function should be assessed before treatment is commenced.

Moderate or severe hepatic impairment

No gender/age discrimination

There are limited pharmacokinetic data for this patient population. However, hepatic metabolism represents the major route of anagrelide clearance and liver function may therefore be expected to influence this process. Therefore it is recommended that patients with moderate or severe hepatic impairment are not treated with anagrelide. The potential risks and benefits of anagrelide therapy in a patient with mild impairment of hepatic function should be assessed before treatment is commenced.